JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

  NCT02955446

  Conditions:   Neoplasm;   Desmoid Tumor
  Intervention:   Drug: PF-03084014
  Sponsors:   University of Colorado, Denver;   SpringWorks Therapeutics, Inc.
  No longer available
• CTL019 Out of Specification MAP for ALL or DLBCL Patients

  NCT03601442

  Conditions:   Acute Lymphoblastic Leukemia (ALL);   Diffuse Large B-cell Lymphoma (DLBCL)
  Intervention:   Biological: CTL019
  Sponsor:   Novartis Pharmaceuticals
  Available
• Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

  NCT03433131

  Conditions:   Narcolepsy Without Cataplexy;   Narcolepsy With Cataplexy
  Intervention:   Drug: Pitolisant
  Sponsor:   Harmony Biosciences, LLC
  Available
• Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

  NCT02624570

  Conditions:   Acute Myeloid Leukemia (AML) With;   FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
  Intervention:   Drug: Midostaurin
  Sponsor:   Novartis Pharmaceuticals
  Available
• This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic

  NCT00244686

  Condition:   Hypereosinophilic Syndrome
  Intervention:   Drug: Mepolizumab
  Sponsor:   GlaxoSmithKline
  Available
• An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

  NCT03154437

  Condition:   Hemophilia A
  Intervention:   Biological: Emicizumab
  Sponsor:   Genentech, Inc.
  Approved for marketing
• Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients

  NCT02473497

  Condition:   Neoplasm
  Intervention:   Drug: Crizotinib
  Sponsor:   Pfizer
  Available
• Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL

  NCT02187354

  Condition:   Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
  Interventions:   Drug: Blinatumomab;   Other: Extension of LTFU as per ProtocolAmendment7 7Jun18
  Sponsor:   Amgen
  No longer available
• Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

  NCT03070093

  Conditions:   Acute Myeloid Leukemia (AML);   FMS-like Tyrosine Kinase-3 (FLT3) Mutations
  Intervention:   Drug: gilteritinib
  Sponsor:   Astellas Pharma Global Development, Inc.
  Available
• An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

  NCT03259633

  Condition:   NF type1 With Inoperable Plexiform Neurofibromas
  Intervention:   Drug: Selumetinib
  Sponsor:   AstraZeneca
  Available
• An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

  NCT03147742

  Condition:   Graft-versus-host Disease (GVHD)
  Intervention:   Drug: Ruxolitinib
  Sponsor:   Incyte Corporation
  Available
• An Open-label Treatment Protocol for VTS-270 in Patients With Neurologic Manifestations of NPC

  NCT03643562

  Condition:   Niemann-Pick Type C Disease
  Intervention:   Drug: VTS270
  Sponsor:   Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company
  Available
• Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

  NCT02477891

  Condition:   Multiple Myeloma
  Intervention:   Drug: Daratumumab
  Sponsor:   Janssen Research & Development, LLC
  Approved for marketing
• An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

  NCT01833039

  Condition:   Relapsed or Refractory Mantle Cell Lymphoma
  Intervention:   Drug: Ibrutinib
  Sponsors:   Janssen Biotech, Inc.;   Pharmacyclics LLC.
  Approved for marketing